<DOC>
	<DOCNO>NCT01015430</DOCNO>
	<brief_summary>This randomize , double-blind multiple ascend dose study evaluate safety tolerability , pharmacokinetics efficacy RO4917523 patient Fragile X Syndrome . The patient randomize receive either active drug placebo . The anticipated time study treatment 6 week . The target sample size &lt; 100 patient .</brief_summary>
	<brief_title>A Study With RO4917523 Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Adult patient , 18 50 year age Fragile X Syndrome IQ le 75 Reliable caregiver Current psychosis presumption psychosis History suicidal behavior consider high suicidal risk Severe selfinjurious behavior Any unstable medical condition Fragile X Syndrome ( e.g . hypertension , diabetes ) Current seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>